Delisting risk
XTL Biopharmaceuticals (ADR) (XTLB)
Develops psychedelic therapies and active ingredients through Psyga Bio.
$2.58
Pre-market−0.08 (−3.01%)
At close$2.66(+14.66%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions6 holders · as of Mar 31, 2026 | 0.77% | 72.7K ADS | |
| Otherremainder | 99.23% | 9.39M ADS |
9.46M ADS (1 ADS = 100 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Institutions13F, as of Mar 31, 2026
6 holders · 72.7K shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Noked Israel Ltd | 49.7K | 0.53% | May 14, 2026 | |
| Smartharvest Portfolios, LLC | 13.4K | 0.14% | Apr 21, 2026 | |
| Rhumbline Advisers | 6.0K | 0.06% | May 12, 2026 | |
| Gamma Investing LLC | 3.4K | 0.04% | Apr 6, 2026 | |
| Tower Research Capital LLC (TRC) | 244 | 0.00% | May 15, 2026 | |
| Morgan Stanley | 10 | 0.00% | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
